ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA ® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013.ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA ® outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon's net sales of JETREA ® . ThromboGenics and Alcon intend to share the costs equally of developing JETREA ® for a number of new vitreoretinal indications. In Europe, JETREA ® is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Alcon has launched JETREA ® in the UK, Germany, Denmark, Norway, Finland and Sweden. ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), also referred to as TB-403. ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at http://www.thrombogenics.com. About Bicycle Therapeutics Bicycle Therapeutics has developed a proprietary bicyclic peptide based technology that enables the discovery of a new class of drug candidates ('bicycles') providing antibody-like affinity and selectivity in a much smaller chemically synthesized molecule. Bicycle peptides are short peptide sequences constrained by a chemical scaffold core to form a structure with two loops of amino acids. This structure confers high stability and high affinity binding to targets. The company is applying the technology to drug discovery projects in areas including oncology and ophthalmology and additional therapeutic areas through selected collaborative discovery partnerships with pharma companies.